EUVIMEDEUVIMED entdecken
Open Access

Prospect of Muscle-Building Supplement HMB in Alzheimer’s Disease

Abhiram Uppalapati, Ahiri Vishnubhotla, Kalipada Pahan iD

Journal of Clinical & Experimental Immunology · 13.07.2026 · 11 (03) · 01-08

DOI: 10.33140/jcei.11.03.01 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical & Experimental Immunology, online erschienen am 13.07.2026. Verfasst von Abhiram Uppalapati und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Sciences, Rush University Medical Center, Chicago, IL. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: BLRD VA, NCCIH NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease (AD) is the most common progressive and irreversible neurodegenerative disorder in humans that affects memory, thinking and behavior. Impairment in synaptic plasticity is one of the hallmarks in AD, with most of the impairment occurring in the hippocampal region, a key part of the brain for memory and learning. Therefore, the upregulation of hippocampal plasticity is critical to remediate the progression of AD and preserve memory formation and cognitive functions. Recent studies have described β-hydroxy-β-methylbutyrate (HMB), a body building supplement commonly used by athletes, as a candidate molecule for improving hippocampal plasticity. Clinically, AD is characterized by the abnormal accumulation of beta amyloid (Aβ) plaques, coupled with intracellular aggregates of hyperphosphorylated tau protein. In addition to enhancing hippocampal plasticity, HMB has been also demonstrated to lower amyloid plaques in a mouse model of AD. Although liver is rich in peroxisome proliferator-activated receptor alpha (PPARα), recent findings have established the presence of PPARα in hippocampus and other parts of the brain. Interestingly, HMB has been shown to utilize PPARα for lowering plaques and increasing hippocampal plasticity. Here, we discuss these newly described features of HMB with possible implications for the use of HMB supplement in patients with dementia and AD.

Schlagwörter

Stichwörter der Autor:innen

ADAM10Alzheimer’s DiseaseAmyloid PlaqueAutophagyCREBHMBHippocampal PlasticityPPARαTFEB

Autor:innen und Institutionen

  • Department of Neurological Sciences, Rush University Medical Center, Chicago, IL.
  • Division of Research and Development, Jesse Brown Veterans Affairs Medical Center, Chicago, IL.

ORCID-Profile: Kalipada Pahan

Förderung

  • BLRD VA
  • NCCIH NIH HHS

Zitieren

APA

Uppalapati, A., Vishnubhotla, A., & Pahan, K. (2026). Prospect of Muscle-Building Supplement HMB in Alzheimer’s Disease. Journal of Clinical & Experimental Immunology, 11(03), 01-08. https://doi.org/10.33140/jcei.11.03.01

Vancouver

Uppalapati A, Vishnubhotla A, Pahan K. Prospect of Muscle-Building Supplement HMB in Alzheimer’s Disease. Journal of Clinical & Experimental Immunology. 2026;11(03):01-08. doi:10.33140/jcei.11.03.01

BibTeX
@article{Uppalapati2026,
  author = {Uppalapati, Abhiram and Vishnubhotla, Ahiri and Pahan, Kalipada},
  title = {Prospect of Muscle-Building Supplement HMB in Alzheimer’s Disease},
  journal = {Journal of Clinical & Experimental Immunology},
  year = {2026},
  volume = {11},
  number = {03},
  pages = {01--08},
  doi = {10.33140/jcei.11.03.01}
}
Kostenlos starten →